NASDAQ:BCDA BioCardia (BCDA) Stock Price, News & Analysis $0.92 +0.01 (+0.58%) As of 10:35 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BioCardia Stock (NASDAQ:BCDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioCardia alerts:Sign Up Key Stats Today's Range$0.88▼$0.9450-Day Range$0.90▼$1.2952-Week Range$0.84▼$2.45Volume15,158 shsAverage Volume126,850 shsMarket Capitalization$10.44 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingHold Company Overview BioCardia, Inc. is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle. The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System. The Helix system is designed to facilitate precise, minimally invasive delivery of cells and biologics into viable myocardium. CardiAMP is an autologous bone marrow-derived progenitor cell therapy under investigation for its potential to improve cardiac function in patients with ischemic heart failure. Both platforms have secured investigational device exemptions from the U.S. Food and Drug Administration and are being evaluated in multi-center clinical trials. Founded in the mid-2000s and headquartered in the San Francisco Bay Area, BioCardia has assembled a leadership team with deep expertise in interventional cardiology, regenerative medicine, and medical device development. Gary S. Margulies, M.D., serves as President and Chief Executive Officer, guiding the company’s clinical programs and strategic partnerships. BioCardia collaborates with academic medical centers and clinical research organizations across the United States to advance its pipeline and ultimately bring new therapeutic options to patients suffering from heart disease.AI Generated. May Contain Errors. Read More BioCardia Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreBCDA MarketRank™: BioCardia scored higher than 75% of companies evaluated by MarketBeat, and ranked 175th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingBioCardia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialBioCardia has a consensus price target of $25.00, representing about 2,642.1% upside from its current price of $0.91.Amount of Analyst CoverageBioCardia has only been the subject of 1 research reports in the past 90 days.Read more about BioCardia's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioCardia are expected to grow in the coming year, from ($0.71) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCardia is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCardia is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioCardia's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.84% of the float of BioCardia has been sold short.Short Interest Ratio / Days to CoverBioCardia has a short interest ratio ("days to cover") of 2.68, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioCardia has recently decreased by 6.09%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioCardia does not currently pay a dividend.Dividend GrowthBioCardia does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.11 News SentimentBioCardia has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for BioCardia this week, compared to 3 articles on an average week.Search Interest6 people have searched for BCDA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added BioCardia to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.7 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $18,796.00 in company stock, which represents 0.1812% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $18,796.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders17.40% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions20.57% of the stock of BioCardia is held by institutions.Read more about BioCardia's insider trading history. Receive BCDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCDA Stock News HeadlinesBioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina FrequencyMay 21 at 8:00 AM | globenewswire.comBioCardia (BCDA) Q1 2026 Earnings TranscriptMay 19 at 9:55 AM | fool.comCould these basic necessities soon be out of reach? Americans must see Nate’s new “Project Fast Cash”Energy costs are up 10%, grocery bills up 16%, and the Chief Investment Officer of Soros Fund Management is warning of a 'painful' 18 to 24 months ahead for everyday Americans. Former construction worker Nate Bear turned $37,000 into $2.7 million in 4 years - and he's now revealing how regular Americans can target 'Fast Cash' trades from the markets each week through his new initiative, 'America's Project: Fast Cash.'May 22 at 1:00 AM | Monument Traders Alliance (Ad)BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company ShowcaseMay 19 at 9:55 AM | markets.businessinsider.comBioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthroughs in Cardiac Therapy and ...May 16, 2026 | finance.yahoo.comBioCardia, Inc. (BCDA) Q1 2026 Earnings Call TranscriptMay 15, 2026 | seekingalpha.comBioCardia Reports First Quarter 2026 Business Highlights and Financial ResultsMay 15, 2026 | globenewswire.comBioCardia, Inc. to Host Conference Call for First Quarter 2026 Financial Results on May 15May 11, 2026 | quiverquant.comQSee More Headlines BCDA Stock Analysis - Frequently Asked Questions How have BCDA shares performed this year? BioCardia's stock was trading at $1.25 on January 1st, 2026. Since then, BCDA shares have decreased by 27.1% and is now trading at $0.9117. How were BioCardia's earnings last quarter? BioCardia, Inc. (NASDAQ:BCDA) released its quarterly earnings results on Friday, May, 15th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.04. Read the conference call transcript. When did BioCardia's stock split? Shares of BioCardia reverse split before market open on Thursday, May 30th 2024.The 1-15 reverse split was announced on Thursday, May 30th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did BioCardia IPO? BioCardia (BCDA) raised $51 million in an initial public offering on the week of July 20th 2015. The company issued 3,900,000 shares at $12.00-$14.00 per share. Cantor Fitzgerald & Co. served as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers. How do I buy shares of BioCardia? Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioCardia own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCardia investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Predictive Oncology (POAI), Abbott Laboratories (ABT), Ford Motor (F) and Wells Fargo & Company (WFC). Company Calendar Last Earnings5/15/2026Today5/22/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 7 days, BCDA's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BCDA CIK925741 Webwww.biocardia.com Phone(650) 226-0120Fax310-861-5299Employees40Year Founded2002Price Target and Rating Average Price Target for BioCardia$25.00 High Price Target$25.00 Low Price Target$25.00 Potential Upside/Downside+2,626.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.23 million Net MarginsN/A Pretax MarginN/A Return on Equity-5,456.14% Return on Assets-232.75% Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio1.12 Sales & Book Value Annual Sales$60 thousand Price / Sales173.92 Cash FlowN/A Price / Cash FlowN/A Book Value($0.09) per share Price / Book-10.19Miscellaneous Outstanding Shares11,380,000Free Float9,396,000Market Cap$10.44 million OptionableOptionable Beta0.56 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:BCDA) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSMX Could Be One of the Most Interesting Small Caps Right NowSMX (Security Matters) is developing molecular-level markers that embed digital identities directly into plast...Smallcaps Daily | SponsoredNew wave of tech IPOs coming?Cerebras surged 68% on its first trading day, hitting a nearly $67 billion valuation - and investors are now a...Mode Mobile | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
